Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

[1]  H. Rammensee,et al.  Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire , 2020, Nature Reviews Clinical Oncology.

[2]  H. Carter,et al.  IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells , 2020, Scientific Reports.

[3]  Baorui Liu,et al.  Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives , 2020, Theranostics.

[4]  Doyeun Kim,et al.  Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1 , 2020, Journal for immunotherapy of cancer.

[5]  Xiaolong Liu,et al.  Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report , 2020, Journal for immunotherapy of cancer.

[6]  K. Livak,et al.  A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. , 2018, Blood.

[7]  D. Bigner,et al.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma , 2018, Clinical Cancer Research.

[8]  Bjoern Peters,et al.  Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis , 2018, Science Immunology.

[9]  Catherine J. Wu,et al.  Towards personalized, tumour-specific, therapeutic vaccines for cancer , 2017, Nature Reviews Immunology.

[10]  D. Neuberg,et al.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. , 2017, Blood.

[11]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[12]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[13]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[14]  T. Shin-I,et al.  Highly functional T-cell receptor repertoires are abundant in stem memory T cells and highly shared among individuals , 2017, Scientific Reports.

[15]  A. Brandes,et al.  OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 , 2017 .

[16]  M. Weller,et al.  The network of immunosuppressive pathways in glioblastoma , 2017, Biochemical pharmacology.

[17]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[18]  Mariella G. Filbin,et al.  Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma , 2016, Nature.

[19]  R. Kefford,et al.  Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases , 2016, British Journal of Cancer.

[20]  Anneliese O. Speak,et al.  T cell fate and clonality inference from single cell transcriptomes , 2016, Nature Methods.

[21]  M. Weller,et al.  Immunosuppressive mechanisms in glioblastoma. , 2015, Neuro-oncology.

[22]  Naoya Hashimoto,et al.  NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP , 2015 .

[23]  Raymond Y Huang,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[24]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[25]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[26]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[27]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[28]  Guang Lan Zhang,et al.  Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunity , 2015, Proceedings of the National Academy of Sciences.

[29]  John N. Weinstein,et al.  PRADA: pipeline for RNA sequencing data analysis , 2014, Bioinform..

[30]  A. Regev,et al.  Preparation of Single‐Cell RNA‐Seq Libraries for Next Generation Sequencing , 2014, Current protocols in molecular biology.

[31]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[32]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[33]  R. McLendon,et al.  Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class , 2013, Clinical Cancer Research.

[34]  David I Heiman,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2013, Nature.

[35]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[36]  D. DeLuca,et al.  Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients , 2012, Clinical Cancer Research.

[37]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[38]  Morten Nielsen,et al.  Prediction of epitopes using neural network based methods. , 2011, Journal of immunological methods.

[39]  Martin Kircher,et al.  Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform , 2011, Nucleic acids research.

[40]  M. DePristo,et al.  ContEst: estimating cross-contamination of human samples in next-generation sequencing data , 2011, Bioinform..

[41]  M. Behlke,et al.  RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers , 2011, BMC biotechnology.

[42]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[43]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[44]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[45]  Dennis C. Friedrich,et al.  A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries , 2011, Genome Biology.

[46]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[47]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[48]  Yi Lin,et al.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. , 2010, Neuro-oncology.

[49]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[51]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[52]  S. Wahl,et al.  Isolation of Human Monocyte Populations , 2005, Current protocols in immunology.

[53]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[54]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[55]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[56]  O. Lund,et al.  NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.